BIA Regional Breakfast - London

‘AI for drug discovery; revolution or just hype?’ 

Join us on Thursday 11 April for another popular BIA networking breakfast. This is an ideal opportunity to meet new business contacts, network with members and hear from local members. We will be discussing whether the tools offered by AI stand to offer real advances in drug development or whether the benefits have been exaggerated.

Time

08:30 - 09:30 Registration, networking and breakfast
09:30 – 10:30 Presentation
10:30 – 11:00 Further networking
 

Venue

Latham & Watkins
99 Bishopsgate
London, EC2M 3XF

Speakers

Steve Bates

Chief Executive Officer

BIA

Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

John Cassidy

Chief Executive Officer

Cambridge Cancer Genomics

John has a background in cancer research in both academia (Cancer Research UK, University of Glasgow, and University of Cambridge) and pharma (MedImmune). His PhD at the University of Cambridge focused on understanding how tumors become resistant to therapy. He also has experience with multiple start-ups.

Noor Shaker

Founder and CEO

Glamorous AI

Before co-founding GTN, Noor was an assistant professor at Aalborg University in Copenhagen working on machine learning with special interest in generative models. She has more than 50 publications and 1200+ citations. She has co-authored a book on generative methods and has won a number of grants and awards for her research. She served as the Chair of the IEEE Games Technical committee and co-organised task forces and conferences.

Mark Warne

Chief Executive Officer

DeepMatter

Mark Warne, was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of Open Orphan plc and Ixico plc.

Mark Swindells

Chief Operating Officer

Exscientia Ltd

Mark spent 7 years working in Japan at the Protein Engineering Research institute in Osaka, Yamanouchi Pharmaceutical Co. Ltd. (now Astellas) and Helix Research Institute . On returning to the UK he worked at Inpharmatica Ltd a biotechnology company focusing on knowledge-based drug discovery founded by Dame Prof Janet Thornton FRS.

Cost

Free for members and non-members